The effect of body mass index on clinical outcomes in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF registry

C.J.F. Camm¹, A.J. Camm², S. Virdone³, J.-P. Bassand⁴, D.A. Fitzmaurice⁵, K.A.A. Fox⁶, S.Z. Goldhaber⁷, S. Goto⁸, S. Haas⁹, A.G.G. Turpie¹⁰, F.W.A. Verheugt¹¹, F. Misselwitz¹², G. Kayani³, K.S. Pieper³, A.K. Kakkar¹³

¹ University of Oxford, Oxford, United Kingdom; ²St George's University of London, Cardiology Clinical Academic Group Molecular & Clinical Sciences Research Institute, London, United Kingdom; ³Thrombosis Research Institute, London, United Kingdom; ⁴Thrombosis Research Institute, London, UNited Kingdom; ⁴Thrombosis Research Institute, London, UK and University of Besançon, Besançon, France; ⁵University of Warwick, Coventry, United Kingdom; ⁶University of Edinburgh, Edinburgh, United Kingdom; ⁷Brigham and Women'S Hospital, Harvard Medical School, Boston, United States of America; ⁸Tokai University School of Medicine, Kanagawa, Japan; ⁹Technical University of Munich, Formerly Department of Medicine, Munich, Germany; ¹⁰McMaster University, Hamilton, Canada; ¹¹Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands (The); ¹²Bayer AG, Berlin, Germany; ¹³Thrombosis Research Institute and University College London, London, United Kingdom

On behalf of GARFIELD-AF Investigators

Funding Acknowledgement: Type of funding source: Private company. Main funding source(s): The GARFIELD-AF registry is funded by an unrestricted research grant from Bayer AG.

Introduction: Higher body mass index (BMI) is associated with a higher risk of atrial fibrillation (AF). However, previous evidence has suggested an inverse association between BMI and risk of AF outcomes.

Purpose: To explore the association between BMI and outcomes in those with newly diagnosed AF in the GARFIELD-AF registry.

Methods: GARFIELD-AF is an international registry of consecutively recruited patients aged \geq 18 years with newly diagnosed AF and \geq 1 stroke risk factor. Data were collected prospectively on 52,080 patients. Participants with missing or extreme BMI values and those without two-year follow-up were excluded. Cox proportional hazard models were used to estimate the effect of BMI on the risk of outcomes. Models were adjusted for age, sex, ethnicity, smoking, alcohol, and \geq moderate chronic kidney disease. Where appropriate participants were divided into groups based on BMI. Restricted cubic splines were used to assess non-linear relationships.

Results: BMI and outcome data were available for 40,495 patients. Those

with higher BMI were generally younger, and more likely to have preexisting hypertension, diabetes, or vascular disease (Table). Underweight patients received anticoagulation less often than those in other groups (60.3% vs 67.9%, respectively). During follow-up, 2,801 participants (6.9%) died and 603 (1.5%) had new/worsening heart failure. Following adjustment for potential confounders, a U-shaped relationship was seen between BMI and all-cause mortality and new/worsening heart failure (Figure). For all-cause mortality, the lowest risk was at 30kg/m². Below this level, there was an 8% higher risk of mortality (95% confidence interval (CI) 6 to 9%) per 1kg/m² lower BMI. Above 30kg/m², there was a 5% higher risk of mortality per 1kg/m² higher BMI (95% CI 4 to 7%). For new/worsening heart failure, the lowest risk was at 25kg/m². Above this level, 1kg/m² higher BMI was associated with an 5% higher risk (95% CI 13 to 6%).

Conclusions: BMI was an important risk factor for both all-cause mortality and new/worsening heart failure in AF. Those at both extremes of BMI are at higher risk.

	Underweight (<18.5kg/m ²)	Normal (18.5 to <25kg/m ²)	Overweight (25 to <30kg/m ²)	Obese (30 to <35kg/m ²)	Very Obese (≥35kg/m ²)	p value
Participants	703	13098	15050	7564	4080	
Male, n (%)	275 (39.1)	7230 (55.2)	9281 (61.7)	4199 (55.5)	1907 (46.7)	< 0.001
Age, median (IQR)	77 (68-84)	73 (64-80)	71 (62–78)	69 (61-76)	66 (59-73)	< 0.001
Diabetes, n (%)	69 (9.8)	2099 (16.0)	3192 (21.2)	2240 (29.6)	1591 (38.9)	< 0.001
Vascular Disease, n (%)	147 (21.0)	2961 (22.8)	3881 (25.9)	2182 (29.0)	1106 (27.3)	< 0.001
Hypertension, n (%)	388 (55.2)	8946 (68.3)	11820 (78.5)	6494 (85.9)	3602 (88.3)	< 0.001

